Acceso a medicamentos esenciales | Referencias y bibliografía

He aquí las referencias que he usado para la redacción de los artículos de esta serie, y para la elaboración de la presentación general.

1. Comprendiendo el acceso a medicamentos esenciales

Hogerzeil, H V. (2004) The Concept of Essential Medicines: Lessons For Rich Countries. BMJ 329: 1169-72. (enlace)

WHO. (1998) Progress Of WHO Member States In Developing National Drug Policies And In Revising Essential Drugs Lists. WHO, Geneva.

WHO. (1999) WHO To Address Trade And Pharmaceuticals. Press Release WHA/13. WHO, Geneva. (enlace)

WHO. (2003) The Selection And Use Of Essential Medicines. Report Of The WHO Expert Committee. Technical Report Series No 914. WHO, Geneva. (enlace)

2. La cadena de barreras.

Aranda H, Herranz E, Peñataro P. (2001) Acceso a Medicamentos Esenciales, Un Reto Al Que Hacer Frente (Access To Essential Medicines, A Challenge To Face) in Farmamundi (ed), Cooperación Al Desarrollo Y Medicamentos Esenciales. Farmamundi, Valencia: 139-152.

DFID. (2006) Factsheet: Access to Medicines. Department for International Development, London. (enlace)

WHO. (2004) WHO Medicines Strategy: Countries at the Core 2004-2007. WHO, Geneva. (enlace)

3. El origen del Acuerdo ADPIC

DFID. (2004) Access To Medicines In Under-Served Markets: What Are The Implications Of Changes In Intellectual Property Rights, Trade And Drug Registration Policy? Department for International Development, Health Systems Resource Center, London. (enlace)

Hoen, H. (2000) Globalisation And Equitable Access to Essential Drugs. (enlace)

Sterckx, S. (2004) Patents And Access To Drugs In Developing Countries: An Ethical Analysis. Development World Bioethics 4, 1: 58-75. (enlace)

WTO. (2003) Fact Sheet: TRIPS And Pharmaceutical Patents. WTO, Geneva. (enlace)

4. Investigación y desarrollo

Elliott R, Bonin MH, Devine C. (2003) Patents, International Trade Law, & Access To Essential Medicines. Médecins sans frontières, Ottawa. (enlace)

GlaxoSmithKline. (2006) WTO And The TRIPS Agreement. (enlace)

Henry D, Lexchin J. (2002) The Pharmaceutical Industry As A Medicines Provider. The Lancet 360: 1590-1595. (enlace)

Hoen, H. (2003) TRIPS, Pharmaceutical Patents And Access To Essential Medicines: Seattle, Doha And Beyond, forthcoming, Moatti JP., Coriat B., Souteyrand Y., et al, Economics of AIDS and Access to HIV-Care. Issues and Challenges for Developing Countries, editions de l’ANRS. (enlace)

MSF. (2001) Fatal Imbalance: The Crisis In Research And Development For Drugs For Neglected Diseases. Médecins sans frontières, Geneva. (enlace)

MSF. (2003) Doha Derailed: A Progress Report On TRIPS And Access To Medicines. Médecins sans frontières, Geneva. (enlace)

5. Patentes y excepciones

Elliott R, Bonin MH, Devine C. (2003) Patents, International Trade Law, & Access To Essential Medicines. Médecins sans frontières, Ottawa. (enlace)

GATT Secretariat. (1994) Annex 1C: Agreement On Trade-Related Aspects Of Intellectual Property Rights. In The Results Of The Uruguay Round Of Multilateral Trade Negotiations. The Legal Texts. WTO, Geneva: 365-403. (enlace)

WHO. (2006a) WTO And The TRIPS Agreement. (enlace)

WHO. (2006b) The Doha Declaration On The TRIPS Agreement And Public Health. (enlace)

WTO. (2003) Fact Sheet: TRIPS And Pharmaceutical Patents. WTO, Geneva. (enlace)

6. Retórica y DOHA

MSF. (2001b) Access To Medicines And The Doha WTO: Why Pattents Matter. (enlace)

MSF. (2004) Briefing Note. Access To Medicines At Risk Across The Globe: What To Watch Out For In Free Trade Agreements With The United States. Médecins sans frontières, Geneva. (enlace)

Rojo, P. (2001) El Acceso A Los Medicamentos Esenciales En Los Países Pobres. Gaceta Sanitaria 15, 6: 540-545. (enlace)

WTO. (2001) Declaration On The TRIPS Agreement And Public Health. Adopted on 14 November 2001. WTO, Doha. (enlace)

WTO. (2005) TRIPS And Public Health: The Situation In Late 2005. (enlace)

WTO. (2006) The Separate Doha Declaration Explained. (enlace)

7. Los otros factores

Bristol-Myers Squibb. (2005) Global Access Program: Access To HIV/AIDS Medicines Through Science, Commitment And Compassion. Brystol-Myers Squibb, Princeton. (enlace)

Kober K, Van Damme W. (2004) Scaling Up Access To Antiretroviral Treatment In Southern Africa: Who Will Do The Job? The Lancet 364: 103-107. (enlace)

Novartis. (2005) Improving Poor People’s Access to Medicine: The Novartis Position. (enlace)

Pfizer. (2005) 2005 Corporate Citizenship Report. Pfizer, New York. (enlace)

Quick, JD. (2003) Ensuring Access To Essential Medicines In The Developing Countries: A Framework For Action. Clinical Pharmacology & Therapeutics 73, 4: 279-283. (enlace)

Schulze, A. (2005) Drugs Are Not Enough. (enlace)

Volver al Índice de El acceso a medicamentos esenciales.